Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cancer clinical trials. Clinical trials programs.

B D Cheson1

  • 1Clinical Investigations Branch, National Cancer Institute, Bethesda, MD 20892.

Seminars in Oncology Nursing
|November 1, 1991
PubMed
Summary

The National Cancer Institute (NCI) leads research on over 100 anti-neoplastic agents in clinical trials. These studies involve cooperative groups, cancer centers, and industry partners, highlighting collaborative cancer drug development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Current Status of U.S. Clinical Trials in Chronic Lymphocytic Leukemia.

Leukemia & lymphoma·2016
Same author

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.

Leukemia·2015
Same author

Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.

Blood cancer journal·2014

Area of Science:

  • Oncology
  • Clinical Pharmacology

Background:

  • The National Cancer Institute (NCI) is a major funder of anti-neoplastic agent research.
  • Over 100 anti-neoplastic compounds are presently undergoing clinical evaluation.

Purpose of the Study:

  • To outline the NCI's significant role in sponsoring anti-neoplastic agent research.
  • To describe the collaborative nature of clinical trials involving these agents.

Main Methods:

  • Review of NCI's sponsorship activities for anti-neoplastic agents.
  • Analysis of clinical trial conduct involving cooperative oncology groups, community programs, cancer centers, and the pharmaceutical industry.

Main Results:

  • The NCI sponsors over 100 anti-neoplastic compounds in clinical testing.
  • Clinical trials are executed by diverse entities including cooperative groups, cancer centers, and industry.

Conclusions:

  • The NCI plays a pivotal role in advancing anti-neoplastic drug development through extensive sponsorship.
  • Clinical trials for anti-neoplastic agents are conducted through both independent and collaborative efforts among various organizations.

Related Experiment Videos